Efficacy of Gymnostemma pentaphyllum in Patients with Hyperlipidemia

Abstract

randomized double blind placebo controlled trial was conducted to determine the efficacy of Gymnostemma pentaphyllum in patients with hyperlipidemia. Twenty-three patients were allocated to receive Gymnostemma pentaphyllum powder in capsule at the dosage of 5 grams thrice a day for 3 months. Twenty-one patients received placebo in identical capsules thrice a day for 3 months. Lipid profiles (cholesterol, triglyceride, high density lipoprotein and low density lipoprotein) were determined prior to take medication and every month thereafter. Lipid profiles of all patients at entry were not significantly different from those after therapy. Lipid profiles of the patients in both groups at month 1, 2 and 3 were not significantly different. Oxidative stress & anti-oxidant activity and anti-platelet activity in the serum samples taken from patients in both groups were not significantly different. Adverse events and abnormal laboratory tests were not observed in patients receiving Gymnostemma pentaphyllum. Most of the patients were satisfied with the treatment they received. It is concluded that Gymnostemma pentaphyllum powder in capsules prepared by Department of Medical Sciences, Ministry of Public Health at the dosage of 5 grams thrice a day for 3 months is safe but not efficacious in reducing lipids in patients with hyperlipidemia.

Keywords

• Gymnostemma pentaphyllum
• Hyperlipidemia